{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:17:02Z","timestamp":1784323022428,"version":"3.55.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Veno-occlusive disease (VOD) is a rare but potentially life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Although increasing awareness and modern transplant techniques have mitigated risk, the interaction of historic risk factors in the current era with posttransplant cyclophosphamide (PTCy) is unknown. We performed a retrospective single-center analysis of adult patients aged \u226518 years undergoing allo-SCT (N\u00a0= 1561) using predominately PTCy as graft-versus-host disease (GVHD) prophylaxis (72%). We found a higher rate of VOD at 16.8% (20 of 119) in those aged \u226425 years compared with 3.8% (55 of 1442) in those aged &amp;gt;25 years, with unique predictors of VOD within each cohort. Multivariate classification and regression tree (CART) analysis confirmed age as the primary independent determinant of the rate of VOD. Among patients aged 18 to 25 years, disease risk index (DRI; 31% with high\/very high DRI vs 12% low\/intermediate DRI; P\u00a0= .03) and prior lines of chemotherapy (24% with &amp;gt;1 vs 6% with \u22641; P\u00a0=\u00a0.03) were the strongest predictors of VOD. Incidence of VOD in patients aged &amp;gt;25 years of age consistently ranged between 3% and 5% across most risk factors evaluated, with only hepatic factors (baseline elevation of bilirubin, aspartate transferase, alanine aminotransferase) or gemtuzumab exposure associated with increased rates of VOD. There was no significant difference in rates of VOD in those receiving PTCy compared with those receiving alternate GVHD prophylaxis. Our data highlight the differences in incidence and predictors of VOD between younger (\u226425) and older (&amp;gt;25) adults undergoing allo-SCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011233","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T19:32:19Z","timestamp":1706124739000},"page":"1128-1136","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Incidence and risk factors of early onset VOD\/SOS differ in younger vs older adults after stem cell transplantation"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-2597","authenticated-orcid":false,"given":"Curtis","family":"Marcoux","sequence":"first","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"2Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima M.","family":"Saliba","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Wallis","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-608X","authenticated-orcid":false,"given":"Sajad","family":"Khazal","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"4Pediatric Hematology-Oncology, Loma Linda University, San Bernardino, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dristhi","family":"Ragoonanan","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Tewari","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-0355","authenticated-orcid":false,"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-6453","authenticated-orcid":false,"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Alousi","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheath","family":"Alatrash","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Srour","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"issue":"12","key":"2024031115251342300_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024031115251342300_bib2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/ajt.16345","article-title":"Early and late-onset veno-occlusive disease\/sinusoidal syndrome post allogeneic stem cell transplantation - a real-world UK experience","volume":"21","author":"Mehra","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"2024031115251342300_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024031115251342300_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2018.07.039","article-title":"Early clinical predictors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after myeloablative stem cell transplantation","volume":"25","author":"Roeker","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9823","key":"2024031115251342300_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"2024031115251342300_bib6","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","article-title":"Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant","volume":"24","author":"Strouse","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024031115251342300_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bbmt.2016.04.011","article-title":"Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research","volume":"22","author":"Strouse","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024031115251342300_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"4","key":"2024031115251342300_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"7","key":"2024031115251342300_bib10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024031115251342300_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","article-title":"Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group","volume":"55","author":"Mohty","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024031115251342300_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024031115251342300_bib13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024031115251342300_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"issue":"3","key":"2024031115251342300_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41409-021-01546-w","article-title":"Low Incidence of hepatic sinusoidal obstruction syndrome\/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin","volume":"57","author":"Stutz","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024031115251342300_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamapediatrics.2015.4689","article-title":"Cancer in adolescents and young adults: a narrative review of the current status and a view of the future","volume":"170","author":"Barr","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"2","key":"2024031115251342300_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024031115251342300_bib18","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2352-3026(19)30201-7","article-title":"Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement","volume":"7","author":"Mahadeo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024031115251342300_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-020-00998-w","article-title":"Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading","volume":"56","author":"Ragoonanan","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024031115251342300_bib20","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1542\/peds.2005-1789","article-title":"Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients","volume":"117","author":"Ouach\u00e9e-Chardin","year":"2006","journal-title":"Pediatrics"},{"issue":"8","key":"2024031115251342300_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bbmt.2007.05.004","article-title":"A\u00a0new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation","volume":"13","author":"Mathews","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2024031115251342300_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","article-title":"Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation","volume":"40","author":"Cheuk","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2024031115251342300_bib23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbmt.2017.02.020","article-title":"Evaluation of the pharmacokinetics and efficacy of a busulfan test dose in adult patients undergoing myeloablative hematopoietic cell transplantation","volume":"23","author":"Weil","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2024031115251342300_bib24","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2174\/138161208785061382","article-title":"Therapeutic drug monitoring of busulfan in transplantation","volume":"14","author":"Russell","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"4","key":"2024031115251342300_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024031115251342300_bib26","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024031115251342300_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/bjh.14727","article-title":"Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day\u00a0+100 survival following haematopoietic stem cell transplantation","volume":"178","author":"Richardson","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2024031115251342300_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/bloodadvances.2021005410","article-title":"Defibrotide: real-world management of veno-occlusive disease\/sinusoidal obstructive syndrome after stem cell transplant","volume":"6","author":"Nauffal","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2024031115251342300_bib29","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1038\/s41409-020-0918-1","article-title":"Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD","volume":"55","author":"Szmit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024031115251342300_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41409-022-01900-6","article-title":"Real-world use of defibrotide for veno-occlusive disease\/sinusoidal obstruction syndrome: the DEFIFrance Registry Study","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2024031115251342300_bib31","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024031115251342300_bib32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024031115251342300_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"2024031115251342300_bib34","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024031115251342300_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"25","key":"2024031115251342300_bib36","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1128\/2217544\/blooda_adv-2023-011233-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1128\/2217544\/blooda_adv-2023-011233-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T15:25:51Z","timestamp":1710170751000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1128\/514723\/Incidence-and-risk-factors-of-early-onset-VOD-SOS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011233","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}